Research & Clinical Insights
Evidence from the clinicians and institutions shaping allergy, asthma, and anaphylaxis policy — featuring Dr. Ruchi Gupta (CFAAR / Northwestern) and Dr. Michael Pistiner (Mass General / Harvard), with a direct citation for every finding.
Research & Clinician Insights
Evidence from the clinicians and institutions shaping allergy, asthma, and anaphylaxis policy. Every finding below links directly to its peer-reviewed source, federal announcement, or the clinician's own program — no fabricated data.
Dr. Ruchi Gupta, MD, MPH
Founding Director, Center for Food Allergy & Asthma Research (CFAAR)
Northwestern University Feinberg School of Medicine & Lurie Children's Hospital
A board-certified pediatrician and one of the nation's leading food allergy epidemiologists. Dr. Gupta's landmark prevalence studies established that food allergy affects roughly 7.6% of U.S. children and 10.8% of adults — and that Black, Hispanic, and low-income families bear a disproportionate share of the burden. Her work underpins much of today's food allergy policy and prevention guidance.
Dr. Michael Pistiner, MD, MMSc
Director of Food Allergy Advocacy, Education and Prevention
Mass General Hospital for Children (Harvard Medical School)
A pediatric allergist devoted to translating food allergy science into practical, school- and community-ready preparedness. Dr. Pistiner co-authored the American Academy of Pediatrics' 2025 clinical report on managing food allergy in schools and is a trusted voice for families, early-childhood providers, and school nurses on anaphylaxis readiness and prevention.
Key Research Findings & Why They Matter for Policy
Food Allergy Prevalence Is Higher Than Once Thought
Roughly 7.6% of U.S. children and 10.8% of adults now have a food allergy — translating to tens of millions of Americans. Adult-onset food allergy is rising, and many adults were never diagnosed in childhood.
CFAAR / FARE population studies (2025–2026)
View sourceXolair (Omalizumab) — First Medication to Reduce Multi-Food Allergic Reactions
In February 2024 the FDA approved omalizumab (Xolair) as the first medication to reduce allergic reactions — including anaphylaxis — from accidental exposure to multiple foods, opening a new era in food allergy treatment beyond strict avoidance.
U.S. FDA (Feb 2024)
View sourceOUtMATCH Trial — NIH-Funded Biologic Breakthrough
The NIH-funded OUtMATCH study (led by Johns Hopkins and consortium investigators) showed omalizumab enabled multi-food-allergic patients to tolerate accidental exposure to multiple allergens — a federally funded milestone shaping tomorrow's treatment guidelines.
Johns Hopkins / NIH (June 2025)
View sourceRacial & Ethnic Disparities in Anaphylaxis and Epinephrine Access
Black and Hispanic children have higher rates of food-induced anaphylaxis and emergency visits, yet are significantly less likely to carry an epinephrine auto-injector or see an allergist. A 2026 peer-reviewed study confirmed Black children have the highest rates of food-induced anaphylaxis.
AAAAI 2025 Position Statement; World Allergy Organization Journal (2026)
View sourceEarly Allergen Introduction Prevents Peanut Allergy
Building on the landmark LEAP study, current NIAID and AAP guidance recommends early introduction of peanut-containing foods to infants at high risk — proven to dramatically reduce peanut allergy development. This prevention science is now the basis for federal infant-feeding policy.
NIH / NIAID
View sourceSchools Need Standardized Food Allergy Management Plans
The American Academy of Pediatrics' 2025 clinical report — co-authored with food allergy experts including Dr. Pistiner — lays out evidence-based school food allergy management, emergency response, and inclusion practices that laws like Elijah's Law aim to make standard nationwide.
American Academy of Pediatrics (2025)
View sourceSpotlight: Early Allergen Introduction
The prevention science that reversed decades of avoidance advice — and now anchors federal infant-feeding policy. Each finding links directly to its peer-reviewed publication or official guideline.
The LEAP Trial — An 81% Reduction in Peanut Allergy
The landmark Learning Early About Peanut Allergy (LEAP) trial, published in the New England Journal of Medicine in 2015 and led by Dr. Gideon Lack, randomized high-risk infants to either consume or avoid peanut-containing foods starting at 4–11 months. Regular early consumption reduced the development of peanut allergy by approximately 81% by age 5 — one of the most consequential prevention findings in modern allergy medicine.
NEJM — Du Toit et al., 2015 (LEAP Trial)
View sourceLEAP-On — Protection Persists After a Year of Avoidance
The LEAP-On follow-up study showed that children who had consumed peanut early maintained their protection even after a 12-month period of avoidance — demonstrating sustained oral tolerance rather than a transient effect that requires constant exposure.
NEJM — Du Toit et al., 2016 (LEAP-On)
View sourceNIAID Addendum Guidelines — Introduce Peanut by 4–6 Months
In 2017 the NIH/NIAID issued an addendum to its food allergy prevention guidelines, recommending that infants at high risk for peanut allergy (severe eczema and/or egg allergy) be introduced to peanut-containing foods as early as 4–6 months of age, after evaluation. This directly translated the LEAP evidence into national prevention policy.
NIH / NIAID Addendum Guidelines (2017)
View sourceAAP Endorses Early Introduction for All Infants
The American Academy of Pediatrics affirms that complementary foods — including potentially allergenic ones — can be introduced from 4–6 months, with no evidence that delaying allergenic foods prevents allergy. The AAP position aligns with the NIAID addendum and supports early, intentional peanut introduction for high-risk infants.
American Academy of Pediatrics
View sourceEAT Study — Broadening Early Introduction Beyond Peanut
The Enquiring About Tolerance (EAT) trial examined early introduction of six allergenic foods (including peanut, egg, and milk) in the general infant population. While adherence challenges limited the primary result, per-protocol analysis showed significantly lower allergy rates among infants who successfully introduced the foods early — supporting broad early introduction as a prevention strategy.
JAMA — Perkin et al., 2016 (EAT Study)
View sourceFARE & CDC — Translating Prevention Science for Families
FARE's Be PAL program and the CDC's infant nutrition guidance promote early introduction of peanut-containing foods to reduce food allergy risk. These community-facing resources convert the peer-reviewed evidence into actionable guidance for families and pediatricians.
FARE; CDC Infant Nutrition
View sourceMore Leading Researchers
Additional clinician-scientists whose work advances food allergy treatment, equity, and prevention \u2014 each profile links to their institution and key research.
Dr. Carla Davis, MD
Director, Texas Children’s Hospital Food Allergy Program
Baylor College of Medicine
A pediatric allergist and immunologist leading one of the nation’s largest food allergy programs. Dr. Davis’s research spans oral immunotherapy, food allergy quality of life, and the inclusion of diverse, historically underrepresented populations in clinical trials. She is a featured voice in FARE’s Living Teal Global Summit panel on addressing racial gaps in food allergy research.
Dr. Kari Nadeau, MD, PhD
Chair, Department of Environmental Health
Harvard T.H. Chan School of Public Health
A physician-scientist and pioneer in food allergy and environmental immunology. Dr. Nadeau’s work on multi-allergen oral immunotherapy and the intersection of environmental exposures with allergic disease has shaped modern treatment paradigms. She previously directed the Sean N. Parker Center for Allergy & Asthma Research at Stanford University.
Dr. Robert Wood, MD
Director, Pediatric Allergy & Immunology
Johns Hopkins University School of Medicine
A leading pediatric allergist whose research has advanced food allergy diagnosis, threshold science, and immunotherapy. Dr. Wood is a principal investigator in the NIH-funded OUtMATCH trial, which demonstrated that omalizumab enabled multi-food-allergic patients to tolerate accidental exposure to multiple allergens — a federally funded milestone in food allergy treatment.
AAAAI Research & Policy Statements
Evidence and policy positions from the American Academy of Allergy, Asthma & Immunology \u2014 the leading professional society of allergist-immunologists \u2014 with direct citations.
AAAAI 2025 Position Statement — Health Disparities in Food Allergy
The American Academy of Allergy, Asthma & Immunology’s 2025 position statement documents that Black and Hispanic patients have higher rates of food-induced anaphylaxis and emergency visits, lower epinephrine auto-injector access, and are underrepresented in the clinical trials that shape treatment approvals — calling for deliberate equity in research and care.
AAAAI Position Statement (2025) — PubMed
View sourceAAAAI / WAO 2025 — Omalizumab Outshines OIT for Multi-Food Allergy
Findings presented at the 2025 AAAAI / World Allergy Organization Joint International Congress showed omalizumab (Xolair) outperforming oral immunotherapy alone for multi-food allergy treatment — reinforcing the FDA’s 2024 approval and reshaping how specialists approach severe, multi-food allergic patients.
AAAAI / WAO 2025 Joint Congress
View sourceAAAAI Impact — Food Allergy Equity Through Research, Practice & Policy
AAAAI’s Impact initiative highlights Dr. Ruchi Gupta’s two decades of equity-focused food allergy research — from early asthma disparities work to prevalence studies showing Black and Hispanic children bear a disproportionate food allergy burden — and the policy changes needed to close the gap.
AAAAI Impact Initiative
View sourceAAAAI — Biologic & Immunotherapy Access Must Keep Pace with Science
AAAAAI underscores that breakthrough biologics and immunotherapies only close the allergy burden if access keeps pace — urging policy that guarantees Medicaid coverage, diverse trial enrollment, and specialist access so the communities most affected benefit first, not last.
AAAAI — Health Disparities & Access
View sourceResearch summaries are drawn from the cited primary sources. Always consult a board-certified allergist for clinical decisions.
While we strive for accuracy, information may change over time. Always double-check and verify against official sources before relying on it.